ArticleHealth science reports2024

Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study.

Xiang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.